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Methods. We evaluated risk factors for doubling of serumThe risk of developing end-stage renal disease in patients with
creatinine or the development of ESRD in the Reduction oftype 2 diabetes and nephropathy: The RENAAL Study.
End Points in NIDDM with the Angiotensin II Receptor An-Background. Diabetic nephropathy has become the single
tagonist Losartan (RENAAL) study, which included 1513 pa-most important cause of end-stage renal disease (ESRD)
tients with type 2 diabetes and nephropathy.worldwide. Strategies to slow the rate of loss of renal function
Results. Univariate analyses demonstrated a group of 23 riskin these patients have been developed. We examined the risk
factors that significantly predicted doubling of serum creatininefactors that predict loss of kidney function (doubling of serum
or ESRD. From these univariate analyses, a multivariate modelcreatinine) or ESRD (dialysis or transplantation) in patients
was developed that demonstrated four independent risk fac-with type 2 diabetes in whom blood pressure was controlled.
tors: proteinuria, serum creatinine, serum albumin, and hemo-
globin level. Proteinuria was the strongest and most consistent
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type 2 diabetic patients, is the single most important cause
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of the increase in incidence and prevalence of ESRD [5]. between 31 and 70 years were part of the inclusion crite-
ria. All patients signed informed consent prior to enroll-Until recently, no study had evaluated interventions de-
signed to reduce the risk of developing ESRD in type 2 ment, and the study was approved by the local Institu-
tional Review Board of each participating center. Afterdiabetics with nephropathy [8, 9]. Results from the Re-
duction of End Points in NIDDM with the Angiotensin II a 6-week run-in period, patients were randomized to treat-
ment with losartan or placebo, and followed up for aAntagonist Losartan (RENAAL) study have revealed
a significant benefit of losartan beyond blood pressure mean of 3.4 years.
Before randomization, baseline blood biochemical stud-lowering on the primary composite end point of doubling
serum creatinine (DsCr), ESRD (defined as dialysis or ies were measured, and urine was obtained for determina-
tion of Alb:Cr ratio. All measurements were performedtransplantation), or death [8]. Benefits were also ob-
served for each of the individual renal end points. The in a central laboratory. Trough blood pressure was mea-
sured three times in a sitting position after a resting perioddatabase from this clinical study provides a unique op-
portunity to evaluate risk factors for the progression of of at least 5 minutes and before ingestion of antihyper-
tensive medications. The average of these measurementsnephropathy in 1513 type 2 diabetics with nephropathy
followed for an average of 3.4 years. was recorded, and the mean arterial pressure was calcu-
lated as diastolic arterial pressure  1/3(systolic arterialIn patients with type 1 diabetes and nephropathy, as
well as in renal diseases not caused by diabetes, factors pressure  diastolic arterial pressure). Pulse pressure,
an index of vascular compliance, was calculated as theassociated with the progressive loss of renal function
have been identified in several prospective and cross- difference between systolic and diastolic blood pressures.
Glomerular filtration rates (GFRest) were estimated forsectional studies [10–17]. Apart from glycemic control,
hypertension, proteinuria, dyslipidemia, and smoking each patient using the Modification of Diet in Renal
Disease (MDRD) formula [19], and expressed as GFRestare among the most important modifiable risk factors.
In addition, age, gender, and serum creatinine level have per 1.73 m2 of body surface area.
The primary outcome measure of the RENAAL studybeen identified as nonmodifiable risk factors that predict
progression of kidney disease. was a composite end point of time-to-first event of DsCr
or ESRD, or death from any cause. An independent,There are no large-scale studies defining risk factors
for progression of kidney disease in patients with ne- blinded end point committee adjudicated all clinical end
points according to rigorous predefined guidelines. Thephropathy attributed to type 2 diabetes [17]. In this re-
port, we systematically evaluated baseline demographic, combined end point used in the present analyses is DsCr
or ESRD.clinical, and laboratory factors to assess their relative
impact on the progression of renal disease as determined
Statistical methodsby DsCr or development of ESRD in the RENAAL study.
Statistical Analysis System version 8 software was used
for all analyses. Baseline differences between genders
METHODS
and among ethnic groups, and the interactions between
Study design gender and ethnic groups, were analyzed using ANOVA
(analysis of variance models), and P values (unadjustedRENAAL was an investigator-initiated, multinational,
double-blind, randomized study comparing losartan ver- for multiplicity) were calculated. Potential risk factors
(including baseline clinical, demographic, and laboratorysus placebo, in addition to conventional antihypertensive
therapy, excluding angiotensin-enzyme converting (ACE) data) were then assessed for association with the com-
posite end point of ESRD or DsCr.inhibitors or other angiotensin II receptor antagonists.
The study was performed in 28 countries and in 250 centers For each of the 29 baseline characteristics (all 16 rou-
tine laboratory parameters and 13 important demo-and involved 1513 patients. The study design, inclusion
and exclusion criteria, and the treatment protocols have graphic variables, chosen a priori), a univariate propor-
tional hazards regression model was used to estimate thebeen reported [8, 18]. Participants were considered to
have type 2 diabetes if they were over 30 years old at relative risk (i.e., the hazard ratio) and its 95% confi-
dence interval. Variables that failed to have a significanttime of diagnosis of diabetes, had no history of diabetic
ketoacidosis, and did not require insulin within 6 months effect were eliminated before developing multivariate
models. For those laboratory variables that demonstratedof diagnosis. Nephropathy was diagnosed if the urinary
albumin:creatinine (Alb:Cr) ratio was 300 mg/g or a substantial co-linearity (such as total serum cholesterol
and low-density lipoprotein cholesterol) only one vari-24-hour urine protein was 500 mg. At randomization,
patients were stratified according to degree of albumin- able was included in the multivariate analyses. A multi-
variate analysis was then performed using a Cox regres-uria (2000 mg/g or 2000 mg/g). A serum creatinine
of 1.3 to 3.0 mg/dL (1.5 to 3.0 mg/dL in males 60 kg); sion model with a stepwise selection process, including all
remaining variables, to identify those with independenta glycosylated hemoglobin A1c (HbA1c) 12%; and age
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effects on the prespecified end points; a P value 0.01 the impact of baseline risk factors on ESRD or DsCr
was similar between genders and among ethnic groupswas required for a variable to be added to the model
and to remain in the model. Patients with missing data (data not shown); therefore, we developed the risk model
for the whole study population.were excluded from the analysis. Urinary Alb:Cr was loga-
rithmically transformed, and patients were censored at the In a subset of patients (N 710) in this study, 24-hour
urine protein was also determined during the baselinetime of death. Once the full regression model was deter-
mined, each independent risk factor was divided into quar- period. The relationship between this 24-hour protein
excretion rate and the measured urinary Alb:Cr ratiotiles, the hazard ratios relative to the lowest-risk quartile
were computed, and the event rates in the quartiles were (on a morning specimen) was then calculated. Because
proteinuria is not normally distributed, data were log-plotted using the Kaplan-Meier approach [20].
transformed prior to analyses, and then back-trans-
formed to the original scale. The equation that best de-
RESULTS
fined the relationship is 24-hour protein excretion 
Baseline clinical, demographic, and laboratory data in 8.9(Alb:Cr)0.79. The Spearman correlation coefficient was
the different ethnic groups by gender 0.9 (P  0.0001). Thus, urinary Alb:Cr ratio was highly
correlated with 24-hour protein excretion rate, and was aData presented here are for the pooled treatment
groups. The multivariate risk model was derived from clinically useful measure of proteinuria in these patients.
only the placebo group and was similar to that derived
Univariate analysis of risk predictors for renal outcomesfor the total population, suggesting that the risk pre-
dictors for progression of kidney disease were indepen- By univariate analysis, we evaluated 29 categorical and
continuous variables; 23 were found to have a significantdent of therapy. In addition, the set of coefficients associ-
ated with the four selected variables did not differ impact on the development of the renal end points in
the study population. There were no major gender-basedsignificantly between the treatment groups (P  0.26).
The RENAAL study provided a unique opportunity differences or ethnic group differences when the combined
or individual renal end points were evaluated by univari-to compare baseline characteristics of various ethnic
groups by gender. There were 956 men and 557 women, ate analysis (data not shown). Therefore, we pooled all
patients and focused our analysis on risk factors for thereflecting the male gender predominance of this disorder.
The average age was 60.3  7.3 years and 60.0  7.5 combined renal endpoints of DsCr or ESRD (Table 2).
In our univariate model, proteinuria, the degree of kid-years for men and women, respectively, proportioned as
735 Caucasians, 277 Hispanics, 252 Asians, 230 Blacks, ney dysfunction and anemia, and serum phosphorus and
albumin levels were strong predictors of DsCr or ESRD.and 19 subjects of other ethnic groups. Table 1 presents
the baseline laboratory and clinical variables stratified Dyslipidemia also was associated with a greater hazard
for development of a renal end point. Systolic blood pres-by ethnic group and gender, along with P values for
differences among ethnic groups and P values for differ- sure, but not diastolic blood pressure, had modest but
significant effect on development of the renal end points.ences between genders. There were no significant inter-
actions between ethnic group and gender, except as Similarly, mean arterial pressure and, to a greater degree,
pulse pressure had a significant effect on the renal endnoted in the table footnote. Several important demo-
graphic and clinical differences were evident among the points. However, it should be recognized that in the
RENAAL study blood pressures were aggressively treatedvarious groups. The urinary Alb:Cr ratio tended to be
highest in Hispanics and Asians, and lowest in Black (target140/90 mm Hg), and the design compared losar-
tan-based conventional antihypertensive therapy to pla-patients; white blood cell counts also tended to be lower
in Blacks. Within each ethnic group, clinical and labora- cebo plus conventional antihypertensive treatment.
When each of the risk factors was divided into quartiles,tory parameters tended to be more abnormal in women.
Except for Asian women, body mass index was higher in the effects of the risks were graded and continuous.
women, consistent with a greater prevalence of obesity.
Multivariate analysis of risk predictors for renal outcomesSystolic, diastolic, and pulse pressures; insulin use; de-
gree of proteinuria; and levels of serum cholesterol and From univariate analysis, we built a multivariate model
using only the significant covariates and eliminating vari-triglycerides were higher in women. Despite higher insu-
lin usage, the degree of glycemic control tended to be ables that demonstrated co-linearity (Table 3). In addition,
we excluded GFRest when constructing this model becauseworse in females. Smoking varied among gender and
ethnic origin, and more Asian and Hispanic men smoked calculation of GFRest included many of the variables that
were of interest in our risk predictions. As in the univariatecompared with women. Thus, at baseline, women ap-
peared to have clinical and laboratory manifestations of analyses, we observed no important gender or ethnic dif-
ferences in covariates that significantly impacted on thetype 2 diabetes and nephropathy that were more abnor-
mal than those of men. Nonetheless, we determined that development of the DsCr or ESRD end point. The influ-
Keane et al: The RENAAL Study1502
T
ab
le
1.
B
as
el
in
e
cl
in
ic
al
de
m
og
ra
ph
ic
an
d
la
bo
ra
to
ry
pa
ra
m
et
er
s
in
va
ri
ou
s
et
hn
ic
gr
ou
ps
by
ge
nd
er
A
si
an
(N

25
2)
B
la
ck
(N

23
0)
H
is
pa
ni
c
(N

27
7)
C
au
ca
si
an
(N

73
5)
P
va
lu
e
fo
r
P
va
lu
e
fo
r
M
al
e
F
em
al
e
M
al
e
F
em
al
e
M
al
e
F
em
al
e
M
al
e
F
em
al
e
et
hn
ic
ge
nd
er
V
ar
ia
bl
e
(N

17
1)
(N

81
)
(N

13
6)
(N

94
)
(N

14
9)
(N

12
8)
(N

49
2)
(N

24
3)
di
ff
er
en
ce
s
di
ff
er
en
ce
s
A
ge
ye
ar
s
59
(7
.4
)
60
(7
.1
)
59
(7
.9
)
59
(7
.4
)
58
(7
.7
)
60
(7
.3
)
61
(7
.3
)
61
(7
.2
)

0.
00
1

0.
23
B
od
y
m
as
s
in
de
xa
kg
/m
2
25
(4
.0
)
25
(5
.3
)
30
(5
.4
)
35
(6
.3
)
27
(5
.7
)
30
(7
.3
)
30
(5
.2
)
33
(6
.4
)

0.
00
1

0.
00
1
In
su
lin
us
e
%
49
57
55
76
53
63
61
75

0.
00
1

0.
00
1
Sm
ok
in
ga

1
ye
ar
28
5
21
19
21
9
19
15

0.
39

0.
00
1
Si
tt
in
g
sy
st
ol
ic
bl
oo
d
pr
es
su
re
m
m
H
g
14
9
(1
7.
1)
15
8
(2
2.
0)
14
9
(1
8.
8)
15
2
(1
8.
3)
14
8
(1
9.
7)
15
3
(1
9.
2)
15
3
(1
8.
5)
15
8
(2
0.
4)

0.
00
1

0.
00
1
Si
tt
in
g
di
as
to
lic
bl
oo
d
pr
es
su
re
m
m
H
g
82
(1
0.
9)
80
(1
0.
4)
84
(1
1.
7)
81
(9
.9
)
83
(9
.9
)
82
(8
.9
)
83
(1
0.
5)
82
(1
0.
5)

0.
54

0.
00
9
M
ea
n
ar
te
ri
al
pr
es
su
re
m
m
H
g
10
4
(1
0.
9)
10
6
(1
2.
2)
10
5
(1
1.
7)
10
5
(1
0.
9)
10
5
(1
1.
2)
10
6
(1
0.
5)
10
6
(1
1.
1)
10
7
(1
1.
9)

0.
1

0.
16
P
ul
se
pr
es
su
re
m
m
H
g
66
(1
6.
1)
78
(1
9.
5)
65
(1
7.
9)
71
(1
6.
3)
65
(1
7.
6)
71
(1
7.
2)
70
(1
7.
0)
76
(1
7.
7)

0.
00
1

0.
00
1
U
ri
ne
A
lb
:C
r
(m
ea
n)
m
g/
g
18
19
(1
52
4)
25
80
(2
39
5)
93
7
(8
43
)
16
23
(1
43
2)
23
07
(1
66
5)
26
59
(2
21
8)
15
91
(1
51
1)
19
86
(1
77
8)

0.
00
1

0.
00
1
A
lb
:C
r
(m
ed
ia
n)
m
g/
g
13
56
21
29
68
6
12
78
14
73
20
75
10
68
14
03

0.
00
1

0.
00
1
Se
ru
m
al
bu
m
in
g/
dL
3.
8
(0
.5
)
3.
8
(0
.4
)
3.
8
(0
.4
)
3.
6
(0
.4
)
3.
7
(0
.5
)
3.
6
(0
.5
)
3.
9
(0
.4
)
3.
8
(0
.4
)

0.
00
1

0.
00
1
Se
ru
m
cr
ea
ti
ni
ne
m
g/
dL
1.
9
(0
.4
)
1.
9
(0
.5
)
1.
9
(0
.4
)
1.
8
(0
.5
)
1.
9
(0
.5
)
1.
8
(0
.5
)
1.
9
(0
.5
)
1.
8
(0
.5
)

0.
25

0.
00
1
G
lo
m
er
ul
ar
fi
lt
ra
ti
on
ra
te
m
L
/m
in
/1
.7
3
m
2
40
(1
0.
3)
34
(1
0.
5)
44
(9
.9
)
39
(1
1.
5)
42
(1
1.
6)
37
(1
1.
6)
44
(1
1.
8)
38
(1
1.
3)

0.
00
1

0.
00
1
Se
ru
m
ch
ol
es
te
ro
l
T
ot
al
m
g/
dL
22
0
(4
9.
7)
24
6
(5
0.
3)
21
3
(4
9.
7)
23
7
(5
6.
6)
22
3
(4
9.
5)
25
4
(5
8.
8)
21
6
(5
3.
9)
24
4
(5
7.
3)

0.
00
5

0.
00
1
L
D
L
m
g/
dL
14
0
(4
7.
7)
15
3
(4
7.
5)
13
3
(4
6.
4)
14
8
(5
0.
2)
14
4
(4
2.
6)
15
8
(5
1.
3)
13
5
(4
1.
8)
14
8
(4
4.
2)

0.
00
4

0.
00
1
H
D
L
m
g/
dL
44
(1
5.
3)
52
(1
8.
8)
48
(1
3.
6)
53
(1
5.
1)
41
(1
2.
1)
48
(1
7.
2)
40
(1
2.
1)
49
(1
5.
8)

0.
00
1

0.
00
1
Se
ru
m
tr
ig
ly
ce
ri
de
s
m
g/
dL
19
7
(1
59
.2
)
23
0
(2
17
.3
)
16
3
(1
14
.1
)
17
6
(1
02
.1
)
21
.6
(1
94
.4
)
24
2
(1
40
.7
)
22
1
(1
88
.6
)
25
5
(2
45
.2
)

0.
00
1

0.
00
5
Se
ru
m
ca
lc
iu
m
m
g/
dL
3.
8
(0
.6
)
9.
4
(0
.6
)
9.
4
(0
.5
)
9.
4
(0
.5
)
9.
3
(0
.5
)
9.
3
(0
.6
)
9.
4
(0
.5
)
9.
5
(0
.5
)

0.
00
2

0.
00
6
Se
ru
m
ph
os
ph
or
us
m
g/
dL
3.
8
(0
.6
)
4.
3
(0
.6
)
3.
7
(0
.6
)
4.
1
(0
.7
)
4.
0
(0
.7
)
4.
3
(0
.6
)
3.
7
(0
.6
)
4.
1
(0
.6
)

0.
00
1

0.
00
1
W
hi
te
bl
oo
d
co
un
ta
m
m
3
7.
4
(1
.8
)
7.
2
(1
.5
)
6.
2
(2
.4
)
7.
0
(2
.1
)
7.
5
(2
.9
)
7.
3
(1
.8
)
7.
6
(1
.9
)
7.
6
(2
.0
)

0.
00
1

0.
46
P
M
N
%
65
(8
)
66
(8
)
59
(1
1)
60
(9
)
65
(8
.2
)
64
(9
)
65
(8
)
63
(1
1)

0.
00
1

0.
02
7
H
em
og
lo
bi
n
g/
dL
12
.8
(1
.9
)
11
.1
(1
.6
)
12
.6
(1
.6
)
11
.0
(1
.3
)
12
.9
(1
.9
)
11
.7
(1
.7
)
13
.3
(1
.6
)
12
.0
(1
.6
)

0.
00
1

0.
00
1
Se
ru
m
ur
ic
ac
id
m
g/
dL
6.
8
(1
.6
)
6.
8
(1
.7
)
7.
0
(1
.6
)
7.
0
(1
.7
)
7.
0
(1
.9
)
6.
5
(1
.7
)
6.
7
(1
.6
)
6.
3
(1
.7
)

0.
00
6

0.
00
2
G
ly
co
sy
la
te
d
he
m
og
lo
bi
n
%
8.
1
(1
.4
)
8.
2
(1
.5
)
8.
9
(1
.8
)
8.
9
(1
.6
)
8.
7
(1
.8
)
9.
0
(1
.9
)
8.
2
(1
.5
)
8.
5
(1
.5
)

0.
00
1

0.
03
6
A
bb
re
vi
at
io
ns
ar
e:
A
lb
:C
r,
al
bu
m
in
cr
ea
ti
ni
ne
ra
ti
o;
L
D
L
,l
ow
-d
en
si
ty
lip
op
ro
te
in
;H
D
L
,h
ig
h-
de
ns
it
y
lip
op
ro
te
in
;P
M
N
,p
ol
ym
or
ph
on
uc
le
ar
le
uk
oc
yt
es
.
a
A
si
gn
if
ic
an
t
in
te
ra
ct
io
n
oc
cu
rr
ed
be
tw
ee
n
ge
nd
er
an
d
et
hn
ic
gr
ou
pi
ng
w
it
h
re
ga
rd
to
bo
dy
m
as
s
in
de
x,
sm
ok
in
g,
an
d
w
hi
te
bl
oo
d
ce
ll
co
un
ts
.F
em
al
es
co
ns
is
te
nt
ly
de
m
on
st
ra
te
d
gr
ea
te
r
bo
dy
m
as
s
in
de
x
ac
ro
ss
al
l
ra
ce
s
ex
ce
pt
A
si
an
s.
A
si
an
an
d
H
is
pa
ni
c
m
en
ar
e
m
or
e
lik
el
y
to
sm
ok
e
th
an
w
om
en
,w
hi
le
B
la
ck
an
d
C
au
ca
si
an
m
en
an
d
w
om
en
sm
ok
e
at
si
m
ila
r
ra
te
s.
M
en
in
al
l
et
hn
ic
gr
ou
ps
,e
xc
ep
t
C
au
ca
si
an
s,
ha
d
lo
w
er
w
hi
te
bl
oo
d
ce
ll
co
un
ts
,w
hi
le
bo
th
A
fr
ic
an
A
m
er
ic
an
m
en
an
d
w
om
en
ha
d
th
e
lo
w
es
t
w
hi
te
bl
oo
d
ce
ll
co
un
ts
.
Keane et al: The RENAAL Study 1503
Table 3. Multivariate analysis for doubling serum creatinine (DsCr)Table 2. Univariate analysis for renal end points of doubling serum
creatinine (DsCr) or end-stage renal disease (ESRD) (N  1513) or end-stage renal disease (ESRD) (N  1300 patients with
available data)
Variable (unit of
measure for hazard Hazard 95%
Hazard Confidenceratio calculation) ratioa 95% CI P value
ratioa interval P value
Age (per 10 years) 0.74 0.66–8.3 0.0001
Male gender (male or female) 0.67 0.56–0.80 0.0001 Urine albumin:creatinine log, mg/g 6.2 4.4–8.7 0.0001
Serum creatinine mg/dL 2.1 1.7–2.5 0.0001Ethnicity (relative to Caucasian)
Asian 1.6 1.3–2.1 0.0001 Serum albumin (per 0.5 g/dL) 0.70 0.61–0.80 0.0001
Hemoglobin g/dL 0.89 0.84–0.95 0.0001Black 1.04 0.8–1.4 0.8
Hispanic 1.8 1.5–2.3 0.0001 a Hazard ratios 1 indicate increasing risk with increasing parameter value
Other 2.7 1.5–4.8 0.0009 (i.e., increasing proteinuria and/or increasing serum creatinine); hazard ratios
Body mass index kg/m2 0.98 0.96–0.99 0.008 1 indicate decreasing risk with increasing parameter value (i.e., decreasing
Sitting systolic blood pressure serum albumin and/or hemoglobin).
(per 10 mm Hg) 1.14 1.09–1.19 0.0001
Sitting diastolic blood pressure
(per 10 mm Hg) 1.07 0.99–1.17 0.1
Pulse pressure mm Hg 1.01 1.01–1.02 0.0001
Mean arterial pressure mm Hg 1.02 1.01–1.03 0.0001 those who were at greater risk for the combined renal
Smoking (1 year) 1.04 0.82–1.31 0.75 endpoint. In individuals with entry serum creatinine of
Insulin use (yes or no) 1.4 1.13–1.64 0.001
2.1 mg/dL, over 60% reached a renal end point duringSerum creatinine mg/dL 2.9 2.5–3.4 0.0001
GFRest mL/min/1.73 m2 0.94 0.93–0.95 0.0001 follow-up (Fig. 1). The relationship between the develop-
Urine Alb:Cr log 13.4 10.2–17.6 0.0001 ment of a renal end point and severity of functional impair-
Serum albumin (per 0.5 g/dL) 0.40 0.37–0.44 0.0001
ment at baseline reflects, in part, that the disease in theseTotal cholesterol (per 100 mg/dL) 1.9 1.3–1.6 0.0001
LDL cholesterol (per 50 mg/dL) 1.4 1.21–1.40 0.0001 individuals is progressing at a rapid rate. Lower hemoglo-
HDL cholesterol mg/dL 1.0 0.99–1.01 0.67 bin and lower serum albumin were significant and inde-
Triglycerides (per log mg/dL) 1.7 1.2–2.4 0.002
pendent risk factors for DsCr or ESRD. As shown inLp(a) (per log mg/dL) 1.004 1.002–1.007 0.0008
Calcium mg/dL 0.34 0.28–0.40 0.0001 Figure 1, even a modest degree of anemia was associated
PO4 mg/dL 2.1 1.8–2.4 0.0001 with increased risk for renal outcomes. Individuals who
Hemoglobin mg/dL 0.75 0.71–0.80 0.0001
had normal hemoglobin (13.8 g/dL) demonstrated aWBC mm3 1.06 1.03–1.09 0.0005
WBC, PMN % 1.02 1.01–1.03 0.001 Kaplan-Meier event rate for DsCr or ESRD that was
HgA1C % 1.01 0.95–1.06 0.85 approximately 20%, whereas those with a hemoglobin of
Uric acid mg/dL 1.01 0.96–1.06 0.79
11.2 g/dL demonstrated a Kaplan-Meier event rate for
Abbreviations are: CI, confidence interval; Alb:Cr, albumin creatinine ratio; DsCr or ESRD that approximated 60% (Fig. 1).GFRest estimated glomerular filtration rate; LDL, low-density lipoprotein; HDL,
high-density lipoprotein; Lp(a), lipoprotein(a) WBC, white blood count; PMN, In the RENAAL study, blood pressure was aggressively
polymorphonuclear leukocytes; PO4, phosphate; HgA1C, glycosylated hemo- treated both at baseline and throughout the study (requir-globin.
a Hazard ratio, change in risk per unit of measure. Hazard ratios 1 indicate in- ing on average 3.6 agents in addition to study drug) to
creasing risk with increasing parameter value (i.e., increasing proteinuria and/or in- levels of approximately 140/75 mm Hg in the losartan orcreasing serum creatinine); hazard ratios1 indicate decreasing risk with increas-
ing parameter value (i.e., decreasing serum albumin and/or hemoglobin). placebo treatment arms. Thus, it is not surprising that
(Log) data were logarithmically transformed prior to analysis. blood pressure per se did not show a major and indepen-
dent effect on renal outcomes.
ence of these risk factors specifically on the DsCr or ESRD DISCUSSION
are presented as Kaplan-Meier curves (Fig. 1) for the Data presented here are for the pooled treatment
entire study population. groups. The multivariate risk model was derived from
From the 23 significant variables noted on univariate only the placebo group and was similar to that derived
analyses, only four had a significant, independent impact for the total population, suggesting that the risk predictors
on the development of the renal end points (Table 3). Of for progression of kidney disease were independent of
note, proteinuria was the most important for achieving therapy. In addition, the set of coefficients associated with
the renal end points, as measured both by the chi-square the four selected variables did not differ significantly be-
value associated with each variable and by the hazard tween the treatment groups (P  0.26). Thus, to increase
ratios associated with the highest risk relative to the lowest the robustness of our analyses, the entire population was
risk quartiles for each variable. The influence of protein- used in this analysis.
uria was striking. Individuals in the highest quartile devel- It is noted that we have excluded death as an end point
oped DsCr or ESRD within 6 to 12 months after initiation in this analysis, which requires us to assume that death is
of the study. By 48 months, the Kaplan-Meier event rate noninformative with respect to renal end points. That is,
approached 80% (Fig. 1). The degree of renal dysfunction, we have to assume that, had they lived, patients who died
would have had renal end points at the rate predicted byas measured by the serum creatinine level, also predicted
Keane et al: The RENAAL Study1504
Fig. 1. Kaplan-Meier estimates of event rate for doubling serum creatinine (DsCr) or end-stage renal disease (ESRD) stratified by quartiles. (A )
Baseline urine albumin creatinine (Alb:Cr) ratio. The hazard ratio (HR) for each quartile was calculated and compared with that of the patients
with the lowest values, who are in the reference quartile with a HR of 1.0. (—), Reference value Alb:Cr ratio 2.6 or 4.4 g protein/24 hours;
(—), Alb:Cr ratio of 1.2 to 2.6 or 2.4 to 4.4 g protein/24 hours; (—), Alb:Cr ratio of 0.56 to 1.1 or 1.3 to 2.3 g protein/24 hours; (···), Alb:Cr ratio
of 0.56 or 1.3 g protein/24 hours. (B ) Baseline serum creatinine. The HR for each quartile was calculated and compared with that of the
patients with the lowest values, who are in the reference quartile with a HR of 1.0. (—), Reference value of serum creatinine 2.1 mg/dL; (—),
serum creatinine 1.8 to 2.1 mg/dL; (—), serum creatinine 1.5 to 1.7 mg/dL; (···), serum creatinine 1.5 mg/dL). (C ) Baseline serum albumin. The
HR for each quartile was calculated and compared with that of the patients with the highest values, who are in the reference quartile with a HR
of 1.0. (···), Reference value of serum albumin 3.6 g/dL; (—), serum albumin 3.6 to 3.8 g/dL; (—), serum albumin 3.9 to 4.0 g/dL; (—) serum
albumin 4.0 g/dL. (D ) Baseline hemoglobin. The HR for each quartile was calculated and compared with that of the patients with the highest
values, who are in the reference quartile with a HR of 1.0. (···), Reference value of hemoglobin 11.2 g/dL; (—), hemoglobin 12.4 to 11.2 g/dL;
(—), hemoglobin 13.8 to 12.5 g/dL; (—), hemoglobin 13.8 g/dL.
their baseline data. There is no way of knowing whether that proteinuria is the most powerful predictor of a renal
event. This finding is of great importance because protein-or not this assumption is true, a limitation of this analysis.
The risk factors for death are quite different than the uria is easily quantifiable by measuring the urinary Alb:Cr
ratio, and is a modifiable risk factor in type 2 diabeticsrisk factors for renal end points. For example, the most
powerful risk factor for death is age, which is not a risk with nephropathy. Unfortunately, many type 2 diabetic
patients who undergo clinical examination with blood pres-factor for renal end points.
The principal new finding of this study is that baseline sure and serum creatinine measurement do not have urine
protein or albumin measured [24]. We found that in clinicalurine Alb:Cr ratio is the most powerful independent pre-
dictor of DsCr or ESRD in type 2 diabetic patients with practice the level of urine Alb:Cr ratio is the most impor-
tant clinical marker for future renal events. Therefore,nephropathy. This relationship was applicable to both gen-
ders and all ethnic groups. In addition, this effect persisted urine Alb:Cr ratio should be measured in all type 2
diabetic patients, whether normotensive or hypertensive.independent of the level of blood pressure. Our findings
regarding the predictive power of proteinuria confirm and In addition to proteinuria and level of renal dysfunc-
tion, our results demonstrated that two other indepen-expand on observational studies in the Pima Indians and
other populations [2–4, 7, 14, 21–23]. In these studies, dent risk factors contributed to the development of DsCr
or ESRD: anemia and hypoalbuminemia. Although theproteinuria was also a powerful predictor of ESRD. Our
findings extend this observation to a larger, ethnically reduction in serum albumin can be explained, in part,
by the magnitude of proteinuria, other factors (e.g., in-diverse population followed carefully in a clinical trial
over an average of 3.4 years. Because of the size and long- flammation and nutrition) may also contribute to this
reduction in serum albumin. In this regard, the relation-term follow-up of our study cohort, we were able to show
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ship of slightly higher total white blood cell count (and of an adverse renal end point is consistent with some,
but not all, recent reports in type 2 diabetes [17, 35–38].specifically polymorphonuclear neutrophil counts) to the
combined renal end point is of interest, suggesting a On the other hand, our finding that a modest degree
of anemia in type 2 diabetic patients with nephropathypotential role for inflammation [25, 26]. Recent studies
have shown that a low serum albumin and hemoglobin affects the progression of kidney disease is novel. Al-
though the mechanism whereby anemia might influenceat the time of initiation of renal replacement therapy is
also associated with increased morbidity and mortality progression of kidney disease is currently unknown, al-
tered oxygen delivery to the interstitial structures of the[27, 28]. Our multivariate analyses reveal that these four
risk factors were of paramount importance in explaining kidney, and changes in cardiac function could potentially
be of importance [39, 40]. The availability of agents toachievement of renal outcomes.
Several potentially important risk factors identified on treat anemia in these patients may benefit renal out-
comes [41–43]; however, it is not known whether anemiaunivariate analysis (such as age, gender, ethnicity, blood
pressure, and lipids) failed to be significantly associated may be a nonmodifiable consequence of more severe
renal disease.with the progression of renal disease in the multivariate
analyses. In this model, male gender had a lower risk
and younger age had a higher risk of progression of
CONCLUSION
kidney disease. However, considering the more severe
Proteinuria is the single most powerful predictor ofdisease present in women, this gender difference was
adverse renal outcomes in association with progressionnot present on multivariate analyses (Table 3). Similarly,
of nephropathy in patients with type 2 diabetes and ne-although Asians and Hispanics, relative to Caucasians,
phropathy. Because proteinuria is not reflected in rou-had a greater risk for a renal end point, proteinuria was
tine laboratory testing unless urinalysis is performed, itmore severe in these populations.
is imperative that it be assessed in all type 2 diabeticAlthough our data indicated that blood pressure failed
patients to identify those at risk for progressive renalto achieve significance in the multivariate analyses, the
disease. The availability of the urinary Alb:Cr ratio asreasons for this are complex. It is known that elevated
a diagnostic test provides an important opportunity toblood pressure, particularly systolic blood pressure, in-
further improve the prognosis of individuals with type 2creases the risk for development of ESRD [7, 29–33].
diabetes and nephropathy.As indicated in the univariate analyses, there was a sig-
nificant effect of blood pressure on renal outcomes. It
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